PARP INHIBITION: ADVANCING THROUGH THE ONCOLYTIC ARENA

被引：3
作者：
Gien, L. T. [2 ]
Mackay, H. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada
[2] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
来源：
DRUGS OF THE FUTURE | 2010年 / 35卷 / 06期
关键词：
POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; DOUBLE-STRAND BREAKS; DNA-REPAIR DEFECT; BRCA MUTANT-CELLS; SPORADIC BREAST; MAMMARY-TUMORS; PHASE-I; TEMOZOLOMIDE; ABT-888; CANCER;
D O I：
10.1358/dof.2010.035.06.1493933
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Poly(ADP-ribose)polymerase 1 (PARP-1) is an essential enzyme in the repair of single-strand breaks in DNA via the base excision repair pathway and has become an important novel target in cancer therapy. PARP inhibitors represent a major breakthrough for patients with hereditary BRCA-associated cancers as a promising new class of anticancer agents. This review will summarize PARP inhibition, including the mechanism of action, its role in the treatment of BRCA1- and 2-associated cancers, the promise of combination therapy with cytotoxic agents and future directions for PARP inhibition in the clinical setting.
引用
收藏
页码：481 / 487
页数：7
相关论文
共 73 条
  • [1] Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
    Albert, Jeffrey M.
    Cao, Carolyn
    Kim, Kwang Woon
    Willey, Christopher D.
    Geng, Ling
    Xiao, Dakai
    Wang, Hong
    Sandler, Alan
    Johnson, David H.
    Colevas, Alexander D.
    Low, Jennifer
    Rothenberg, Mace L.
    Lu, Bo
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (10) : 3033 - 3042
  • [2] The PARP superfamily
    Amé, JC
    Spenlehauer, C
    de Murcia, G
    [J]. BIOESSAYS, 2004, 26 (08) : 882 - 893
  • [3] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    Ashworth, Alan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3785 - 3790
  • [4] Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining
    Audebert, M
    Salles, B
    Calsou, P
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (53) : 55117 - 55126
  • [5] Audeh MW, 2009, J CLIN ONCOL, V27
  • [6] Baldwin RL, 2000, CANCER RES, V60, P5329
  • [7] A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma
    Bedikian, Agop Y.
    Papadopoulos, Nicholas E.
    Kim, Kevin B.
    Hwu, Wen-Jen
    Homsi, Jade
    Glass, Michelle R.
    Cain, Suzanne
    Rudewicz, Patrick
    Vernillet, Laurent
    Hwu, Patrick
    [J]. CANCER INVESTIGATION, 2009, 27 (07) : 756 - 763
  • [8] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917
  • [9] Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns
    Caiafa, Paola
    Guastafierro, Tiziana
    Zampieri, Michele
    [J]. FASEB JOURNAL, 2009, 23 (03) : 672 - 678
  • [10] Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361
    Calabrese, CR
    Almassy, R
    Barton, S
    Batey, MA
    Calvert, AH
    Canan-Koch, S
    Durkacz, BW
    Hostomsky, Z
    Kumpf, RA
    Kyle, S
    Li, J
    Maegley, K
    Newell, DR
    Notarianni, E
    Stratford, IJ
    Skalitzky, D
    Thomas, HD
    Wang, LZ
    Webber, SE
    Williams, KJ
    Curtin, NJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01) : 56 - 67
12345678